Tech Center 1600 • Art Units: 1611 1614 1628
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18708916 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 18259356 | PROCESS FOR THE DIASTEREOMERICALLY PURE PREPARATION OF DL/LD-METHIONYLMETHIONINE | Non-Final OA | Evonik Operations GmbH |
| 18615080 | COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2 | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18330185 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Non-Final OA | AbbVie Inc. |
| 18317725 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | Final Rejection | AbbVie Inc. |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | Non-Final OA | AbbVie Inc. |
| 18471912 | SIRT6 ACTIVATORS | Non-Final OA | The Board of Regents of The University of Texas System |
| 18040858 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-L1) EXPRESSION | Non-Final OA | The Johns Hopkins University |
| 17735753 | COMPOSITION COMPRISING ALKYLCELLULOSE, INCOMPATIBLE HYDROCARBON AND SILICONE OILS AND METHOD EMPLOYING IT | Final Rejection | L'OREAL |
| 17596779 | COMPOSITIONS AND METHODS USING THYMOL AND/OR CARVACROL FOR INDUCTION OF AUTOPHAGY | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18141086 | PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17998204 | PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | Non-Final OA | Janssen Pharmaceutica NV |
| 18612306 | Methods of Treating Neurologic Disorders | Non-Final OA | GEORGETOWN UNIVERSITY |
| 17642732 | COSMETIC COMPOSITION WITH ENHANCED COLOR STABILITY | Final Rejection | Conopco, Inc., d/b/a UNILEVER |
| 18759232 | Treatment of Pneumonia | Non-Final OA | COMBIOXIN SA |
| 18249829 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 17773775 | METABOLIC REPROGRAMMING OF IMMUNE CELLS TO ENHANCE THE EFFICACY OF PROPHYLACTIC AND THERAPEUTIC VACCINES | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18027144 | N-((1-BENZYLPIPERIDIN-3-YL)METHYL)-N-(2-METHOXYETHYL)NAPHTHALENE-2-SULFONAMIDE FOR THE TREATMENT OF CANINE COGNITIVE DYSFUNCTION AND OTHER FORMS OF DEMENTIA IN DOGS | Final Rejection | UNIVERZA V LJUBLJANI |
| 18269042 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Non-Final OA | CHIESI FARMACEUTICI S.P.A. |
| 18595072 | LIPOSOME VITAMIN C PREPARATION | Non-Final OA | ONE INNOVATION LABS, LLC |
| 17599997 | ARTHROPOD CONTROLLING COMPOSITION | Final Rejection | FIRMENICH SA |
| 18577129 | NANOPARTICLES FOR CANCER TREATMENT | Non-Final OA | Immix Biopharma, Inc. |
| 18386828 | Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders | Non-Final OA | Corcept Therapeutics Incorporated |
| 18456718 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Final Rejection | Arvinas Operations, Inc. |
| 17929511 | METHODS AND SYSTEMS FOR NITRIC OXIDE THERAPY FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | Non-Final OA | KNOW Bio, LLC |
| 17290857 | ARTIFICIAL TEARS | Non-Final OA | WATERFORD INSTITUTE OF TECHNOLOGY |
| 18018663 | EMULSIFIER COMPOSITION FOR PERSONAL CARE FORMULATION | Non-Final OA | Lubrizol Advanced Materials, Inc. |
| 18265933 | COMBINATION THERAPY COMPRISING UNCARIA FOR TREATING ANXIETY AND DEPRESSION | Non-Final OA | The Open University |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 17343326 | Increasing Drug Bioavailability In Naltrexone Therapy | Final Rejection | Nalpropion Pharmaceuticals LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy